Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$717.6MCash, Jun 2026
35moCash Runway (est.)
+18%Share Count, 1 Year
Follow CLDX by emailGet an email when CLDX pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about CLDX, unsubscribe in one click. Privacy
📣 What CLDX Says Is Next
in 2027 · “The Company intends to present the EMBARQ-CSU data at an upcoming medical meeting and plans to submit a Biologics License Application (BLA) to the FDA in 2027.”
Company press release, Sep 22, 2026 · SEC filing
late 2026 · “Topline data from this study are expected to be presented in late 2026.”
Company press release, Aug 6, 2026 · SEC filing
Q4 2026 · “Topline data are anticipated in Q4 2026, supporting a planned BLA filing in 2027.”
Company press release, May 7, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
💰 Cash Runway & Dilution Risk
CLDX reported $717.6M in cash and short-term investments (as of Jun 30, 2026) and used about $62M/quarter in operations, an estimated runway of 34.7 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:17 · Low
Cash runway 35 months
ATM program on file since Feb 2024 +15
Shelf registration (S-3ASR, Nov 2023) +10
Company says cash lasts through 2028 -15We believe that the cash, cash equivalents and marketable securities at June 30, 2026 are sufficient to meet estimated working capital requirements and fund current planned operations through 2028.10-Q, Aug 2026
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CLDX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.